People · Operator
Named in public records as an officer, director or promoter · active 2012–2016 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Harrow Health, Inc. | — | Pharmaceuticals | Series A | $29.2M | $226.3M | 2012 |
| Soft Science, Inc. | — | Other | Series A | $10.2M | $84.7M | 2014 |
Robert Kammer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Kammer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Teresa F. Sparks | 1 | 30 |
| Richard Lindstrom | 1 | 13 |
| Paul Finnegan | 1 | 11 |
| Richard L Lindstrom | 1 | 8 |
| Mark L. Baum | 1 | 5 |
| Mark Baum | 1 | 4 |
| Andrew Boll | 1 | 3 |
| Joachim Schupp | 1 | 2 |
| Andrew R. Boll | 1 | 1 |
| Stephen G. Austin | 1 | 1 |
| William H. Nelson | 1 | 1 |
| Peter Case | 1 | 1 |
| Scott Seamans | 1 | 1 |
| Peter Seamans | 1 | 1 |
| R Larry Van Horn | 1 | 1 |
| Anthony Principi | 1 | 1 |
| Stephen Austin | 1 | 1 |
| Peter A Case | 1 | 1 |
| Kenneth D Downey | 1 | 1 |
| John Duerden | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.